NAD footcare case
This article was originally published in The Tan Sheet
Profoot Footcare Products' labeling claim that Triad Insoles "relieves knee, leg and back pain" should be discontinued due to lack of supporting scientific evidence, National Advertising Division says in recent NAD Case Reports. Dr. Scholl's marketer Schering-Plough challenged the claim, asserting it is "unqualified and overly broad as it does not distinguish" between different types of pain. Although Profoot explained the Triad design "incorporates a cupped heel for foot stability and an anatomically conforming supportive arch" to alleviate joint pressure, NAD agrees with Schering based on lack of clinical data. Profoot, while disagreeing, said it would amend the claim in future packaging...
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.